Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | PDE8A | O60658 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | PDE6A | P16499 | 1/20 | 0.34 |
| ▸ | PDE6G | P18545 | 1/20 | 0.34 |
| ▸ | PDE6B | P35913 | 1/20 | 0.34 |
| ▸ | PDE6C | P51160 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232091 | 0.73 | PDE4A (0.47) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8148622 | 0.73 | PDE4A (0.32) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23619220 | 0.68 | ALDH1A1 (0.33) | PDE4APDE4BPDE4CPDE4DPDE2A | |
| SCHEMBL23619444 | 0.68 | PDE4A (0.35) | PDE4APDE4BPDE4CPDE4DPDE2A | |
| 3-Methylxanthine SCHEMBL12013792 | 0.67 | ADORA2A (0.46) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8148624 | 0.67 | ADORA2B (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22072395 | 0.66 | PDE4A (0.42) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23619261 | 0.65 | PDE2A (0.31) | PDE4APDE4BPDE4CPDE4DPDE2A | |
| SCHEMBL22071855 | 0.65 | MEN1 (0.33) | PDE4APDE4BPDE4CPDE4DPDE2A | |
| SCHEMBL2707128 | 0.64 | RPA1 (0.50) | MEN1KMT2APDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997691-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2023-11-07 | — | — | CN | claimed |
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | claimed |
| EP-2434895-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2012-04-04 | — | — | EP | claimed |
| WO-2010132127-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-11-18 | — | — | WO | claimed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | claimed |
| JP-H08507068-A | — | — | 1996-07-30 | — | — | JP | claimed |
| EP-0686157-A1 | 2-BENZYL-POLYCYCLIC GUANINE DERIVATIVES AND PROCESS FOR PREPARING THEM | SCHERING CORPORATION (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1994019351-A1 | 2-BENZYL-POLYCYCLIC GUANINE DERIVATIVES AND PROCESS FOR PREPARING THEM | SCHERING CORPORATION (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | claimed |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | disclosed |
| CN-110997691-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| EP-2081431-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008070095-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008063505-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2003047588-A1 | KIT FOR REDUCING ACHING CAUSED BY PDE-V INHIBITORS | PFIZER LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| WO-1999059584-A1 | COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | SCHERING CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0423805-A2 | Condensed purine derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | PNP 97/4885PDE4A 128/4885PDE4B 125/4885 |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA1, ADORA2B | PNP 97/4885PDE4A 128/4885PDE4B 125/4885 |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | PDE12, PDE5A, PDE3A | PNP 396/4885PDE4A 6/4885PDE4B 12/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PNP 149/4885PDE4A 10/4885PDE4B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.